Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma
Authors:
- 12 January 2015
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 66 (4) , 508-516
Abstract
AimsTo investigate AT-rich interactive domain-containing protein 1A (ARID1A) and p53 expression in small intestinal carcinoma (SIC) and to determine its prognostic significance. Methods and resultsImmunohistochemical staining for ARID1A and p53 was performed in 178 SICs using a tissue microarray (TMA). Loss of or low ARID1A expression was observed in 36 (20.2%) and 60 (33.7%) of cases, respectively. Aberrant p53 expression was observed in 99 (55.6%) cases. Loss of or low ARID1A expression was found to be associated with signet ring cell carcinoma and undifferentiated carcinoma, a high-grade tumour, and a higher T stage. No relationship was found between aberrant p53 expression and clinicopathological factors or overall survival. Patients with loss of ARID1A expression, irrespective of p53 expressional status, showed significantly poorer overall survival than those expressing ARID1A. Multiple regression analysis revealed that grade and pT stage were associated significantly with ARID1A loss, and multivariate analysis showed that patients with high ARID1A expression had a lower risk of death than those with loss of ARID1A expression. ConclusionsLow or loss of ARID1A expression is correlated significantly with a high-grade tumour, higher T stage, and poorer overall survival. These findings suggest that ARID1A expression could be used as a prognostic marker in SIC.Keywords
Funding Information
- Yeungnam University Research Grant (214A380040)
This publication has 35 references indexed in Scilit:
- The roles of ARID1A in gynecologic cancerJournal of Gynecologic Oncology, 2013
- Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric CancerPLOS ONE, 2012
- Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian CancersInternational Journal of Gynecological Cancer, 2012
- Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot AssessmentJournal of Cancer, 2012
- ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic CancersCancer Research, 2011
- Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor typesHuman Mutation, 2011
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladderNature Genetics, 2011
- Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell CarcinomaInternational Journal of Molecular Sciences, 2010
- p53 in health and diseaseNature Reviews Molecular Cell Biology, 2007
- Mutational activation of the RAS‐RAF‐MAPK and the wnt pathway in small intestinal adenocarcinomasScandinavian Journal of Gastroenterology, 2004